Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Skin sensitisation

Currently viewing:

Administrative data

Endpoint:
skin sensitisation: in vivo (non-LLNA)
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: publication meets generally accepted scientific principles, without detailed documentation, acceptable for assessment

Data source

Reference
Reference Type:
publication
Title:
Occupational eczema from N-isopropyl-N' phenylparaphenylenediamine (IPPD) and N-dimethyl-1,3 butyl-N'-phenylparaphenylenediamine (DMPPD) in tyres.
Author:
Herve-Bazin B, Gradiski D, Duprat P, Marignac B, Foussereau J, Chevalier C, Bieber P
Year:
1977
Bibliographic source:
Contact Dermatitis 3: 1-15

Materials and methods

Principles of method if other than guideline:
Method: other: according to Magnusson & Kligman (1969)
GLP compliance:
not specified
Type of study:
guinea pig maximisation test
Justification for non-LLNA method:
Published study. The guinea pig maximisation test was conducted in the year 1977 or before (GPMT, Herve, 1977). At this time point a no reliable guideline was available for the conduction of a LLNA.

Test material

Constituent 1
Chemical structure
Reference substance name:
N-isopropyl-N'-phenyl-p-phenylenediamine
EC Number:
202-969-7
EC Name:
N-isopropyl-N'-phenyl-p-phenylenediamine
Cas Number:
101-72-4
Molecular formula:
C15H18N2
IUPAC Name:
N1-phenyl-N4-(propan-2-yl)benzene-1,4-diamine
Details on test material:
IPPD

In vivo test system

Test animals

Species:
guinea pig
Strain:
Hartley
Sex:
female

Study design: in vivo (non-LLNA)

Inductionopen allclose all
Route:
intradermal and epicutaneous
Vehicle:
other: 1% vaseline
Concentration / amount:
induction (intradermal: 0.5 % in olive oil, epicutaneous: 1% vaseline),
Challengeopen allclose all
Route:
other: epicutaneous
Vehicle:
other: 1% vaseline
Concentration / amount:
induction (intradermal: 0.5 % in olive oil, epicutaneous: 1% vaseline),
No. of animals per dose:
20
Details on study design:
1st application: Induction 0.5 % intracutaneous
2nd application: Challenge 0.05 % open epicutaneous
3rd application: Challenge 0.5 % open epicutaneous

Results and discussion

In vivo (non-LLNA)

Resultsopen allclose all
Reading:
1st reading
Hours after challenge:
48
Group:
negative control
Dose level:
0.05%
No. with + reactions:
0
Total no. in group:
20
Clinical observations:
no data
Remarks on result:
other: Reading: 1st reading. . Hours after challenge: 48.0. Group: negative control. Dose level: 0.05%. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: no data.
Reading:
1st reading
Hours after challenge:
48
Group:
negative control
Dose level:
0.5 %
No. with + reactions:
0
Total no. in group:
20
Clinical observations:
no data
Remarks on result:
other: Reading: 1st reading. . Hours after challenge: 48.0. Group: negative control. Dose level: 0.5 %. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: no data.
Reading:
1st reading
Hours after challenge:
48
Group:
test chemical
Dose level:
0.05 %
No. with + reactions:
2
Total no. in group:
20
Clinical observations:
no data
Remarks on result:
other: Reading: 1st reading. . Hours after challenge: 48.0. Group: test group. Dose level: 0.05 %. No with. + reactions: 2.0. Total no. in groups: 20.0. Clinical observations: no data.
Reading:
1st reading
Hours after challenge:
48
Group:
test chemical
Dose level:
0.5%
No. with + reactions:
14
Total no. in group:
20
Clinical observations:
no data
Remarks on result:
other: Reading: 1st reading. . Hours after challenge: 48.0. Group: test group. Dose level: 0.5%. No with. + reactions: 14.0. Total no. in groups: 20.0. Clinical observations: no data.

Any other information on results incl. tables

TS concentration   % sensitization   sensitizing potential
0.05 % TS               10 %              low
0.5  % TS               90 %              high
controls                 0 %                 -
Potency categorisation based on GPMT:strong
-Clinical signs: not reported

The authors also noted a cross-sensitization to
N-phenyl-N'-cyclohexyl-p-phenylenediamine (CPPD): 90 % of animals  sensitized to 

IPPD showed cross-sensitization to 0.05 % CPPD in vaseline.  Animals sensitized 

to p-phenylenediamine (PPD) or to  N-dimethyl-1,3butyl-N'-phenyl-paraphenylenediamine (6PPD) showed also cross-sensitization  to IPPD (see table).

Table: Cross-Sensitization in guinea pigs (% animals cross-sensitized)
      Cross-reaction product tested (0.05 % in vaseline):
Sensitizer:  CPPD    6PPD     PPD     IPPD
CPPD             50       5         15         nd
6PPD             30      50         nd         nd
PPD             100      95         80         95
IPPD             90      85        100         10

Applicant's summary and conclusion

Interpretation of results:
Category 1 (skin sensitising) based on GHS criteria